| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701695 | Journal of Thoracic Oncology | 2017 | 24 Pages |
Abstract
The MTD of the combination of crizotinib and erlotinib in patients with advanced NSCLC was crizotinib, 150 mg twice daily, with erlotinib, 100 mg once daily, which is less than the approved dose of either agent. The phase II portion of the study was not initiated.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sai-Hong Ignatius MD, PhD, Ramaswamy MD, Keith D. MD, PhD, Gregory A. MD, Martin E. MD, Alain C. MD, Athanassios MD, Nicoletta M. MD, PharmD, Tiziana BSc, Weiwei PhD, Steffan N. MD, PhD, Francisco MD,